Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Sioux Falls, South Dakota

Cancer biologic therapy trials in Sioux Falls, SD

35 cancer biologic therapy studies are recruiting participants at sites in Sioux Falls as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Sioux Falls at a glance

  • 35 studies are recruiting at a site in Sioux Falls.
  • By phase: Phase 1/2 (3), Phase 2 (12), Phase 2/3 (1), Phase 3 (19).
  • By sponsor: industry (15), government (10), university, hospital or other (10).
  • By research area: Lung Cancer (16), Lymphoma (10), Breast Cancer (6), Melanoma (3).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Sioux Falls

Basic details from each study's public record (the 30 most recently updated of 35). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT05564377 · updated
  2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Sanford Cancer Center ( Site 0059)
    Registry record
    NCT06393374 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Avera McKennan Hospital ( Site 0002)
    Registry record
    NCT06966700 · updated
  4. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Sioux Falls, SD on ClinicalTrials.gov.

Lung cancer studies recruiting in Sioux Falls

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06498635 · updated
  2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Avera Cancer Institute ( Site 3209) · Sanford Cancer Center ( Site 3266)
    Registry record
    NCT07513376 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06096844 · updated
  5. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Avera Cancer Institute- Research ( Site 0090) · Sanford Cancer Center ( Site 0053)
    Registry record
    NCT06312137 · updated
  6. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Sanford Cancer Center
    Registry record
    NCT06646276 · updated
  7. KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Sanford Cancer Center Oncology Clinic ( Site 0038)
    Registry record
    NCT07252739 · updated
  8. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT04181060 · updated
  9. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Sanford Cancer Center ( Site 0038)
    Registry record
    NCT04165070 · updated
  10. A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Sanford Cancer Center ( Site 0038)
    Registry record
    NCT06731907 · updated
  11. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06031688 · updated
  12. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06616584 · updated
  13. Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT05624996 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Sioux Falls, SD on ClinicalTrials.gov.

Melanoma studies recruiting in Sioux Falls

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT05136196 · updated
  2. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0071)
    Registry record
    NCT02332668 · updated
  3. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Avera Cancer Institute
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Sioux Falls, SD on ClinicalTrials.gov.

Lymphoma studies recruiting in Sioux Falls

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06317662 · updated
  2. A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Avera Cancer Institute- Research ( Site 5437)
    Registry record
    NCT05947851 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Sanford Cancer Center ( Site 0143)
    Registry record
    NCT06717347 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT05675410 · updated
  6. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Sanford Cancer Center Oncology Clinic · Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT05976763 · updated
  7. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015)
    Registry record
    NCT06395103 · updated
  8. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Avera Cancer Institute
    Registry record
    NCT06500273 · updated
  9. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT06124157 · updated
  10. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Sanford USD Medical Center - Sioux Falls
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Sioux Falls, SD on ClinicalTrials.gov.

Ask about studies near Sioux Falls

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call